Press releases

KANE BIOTECH ANNOUNCES POSITIVE RESULTS
FOR LEAD PRODUCT IN URINARY CATHETER STUDY

WINNIPEG, Manitoba (November 23, 2005) - Kane Biotech Inc. (TSX-V:KNE), a leading biofilm company, is pleased to announce significant positive results in an in vivo study with KBI-5898, the Company's lead product for coating urinary catheters for the prevention of urinary catheter related infections.

The pre-clinical study, sponsored by Kane Biotech, was designed using a recognized in vivo model with two key endpoints. The first endpoint was a reduction in bacterial colonization on the catheter surface. The second endpoint was a reduction in catheter related infection, as measured by testing for the presence of bacteria at the site surrounding the catheter. The study had three test groups; urinary catheters coated with KBI-5898, silver-hydrogel coated urinary catheters, and uncoated urinary catheters. Silver-hydrogel was selected for comparison in the study as it is the current market standard for anti-microbial urinary catheters.

Study results demonstrated that KBI-5898 coated urinary catheters were significantly less likely to be colonized by bacteria than either the silver-hydrogel coated catheters or uncoated catheters. More specifically, 2 of 28 (7%) catheter segments coated with KBI-5898 were colonized, compared to 25 of 28 (89%) coated with silver-hydrogel and 18 of 28 (64%) uncoated catheters.

Furthermore, the study showed that KBI-5898 coated urinary catheters were also significantly less likely to cause catheter related infections than either the silver-hydrogel coated or uncoated catheters. In the study, the rate of infection with catheters coated with KBI-5898 was dramatically reduced with only 1 of 28 (4%) segments developing an infection, compared to 12 of 28 (43%) coated with silver-hydrogel and 14 of 28 (50%) uncoated catheters.

All results comparing KBI-5898 to other test groups were statistically significant.

"This study clearly established that urinary catheters coated with KBI-5898 were superior to both uncoated and silver-hydrogel coated catheters in their ability to protect against catheter related infection", stated Mr. Gord Froehlich, Vice President, Business Development for Kane Biotech. "These results visibly demonstrate the potential of our product to impact the occurrence of urinary tract infections, the single most common type of hospital acquired infection."

Kane Biotech continues to aggressively pursue its commercialization strategy for KBI-5898. Infections caused by urinary catheters cost the United Sates healthcare system over US$1 billion per year. In addition, the Company is also developing an oral care product based on its novel CSP technology for the prevention of dental plaque. The U.S. dental market is over US$70 billion per year.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.